Literature DB >> 23212205

Worse-than-usual visual fields measured in retinitis pigmentosa related to episodically decreased general health.

Ava Katherine Bittner1, Jennifer A Haythornthwaite, Marie Diener-West, Gislin Dagnelie.   

Abstract

BACKGROUND/AIMS: We examined whether retinitis pigmentosa (RP) subjects' worse-than-usual vision measures were related to episodic changes in psychosocial factors and/or general health.
METHODS: In a prospective, cohort study, 37 RP subjects self-administered personal computer (PC)-based visual acuity (VA), contrast sensitivity (CS) and visual field (VF) tests at home twice a week, for 16 sessions in 2-3 months. Subjects rated their general health prior to each vision test session, and completed the Perceived Stress Scale, Positive and Negative Affect Schedules, and Epworth and Stanford Sleepiness Scales immediately after each session.
RESULTS: Nine subjects with reduced mean VA >0.5 log minimal angle of resolution (logMAR) on average had statistically significant 26% more sessions with measured deviations ≥0.1 logMAR from their mean (95% CI 20% to 32%; p<0.001), which were not significantly related to changes in psychosocial factors or general health. Measured deviations ≥0.1 logCS from mean CS were not statistically significantly related to any measured factors. We found a statistically significant increased frequency of sessions with ≥20% VF reduction from the mean (p<0.001) as mean log VF area was reduced. Subjects reporting reduced general health during a session had a statistically significant over twofold greater odds of having a VF reduction from the mean beyond 1 SD (95% CI 1.26 to 5.00; p=0.009).
CONCLUSIONS: Measured episodic VF reductions were more common in advanced RP and related to decreased general health at a session, which should be considered during clinical examinations and trials when determining true changes in vision. We did not find evidence that fluctuations in psychosocial factors were significantly correlated with vision reductions across subjects.

Entities:  

Mesh:

Year:  2012        PMID: 23212205      PMCID: PMC4001740          DOI: 10.1136/bjophthalmol-2012-302116

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  16 in total

Review 1.  Measurement properties of the Epworth sleepiness scale.

Authors:  Michael S Miletin; Patrick J Hanly
Journal:  Sleep Med       Date:  2003-05       Impact factor: 3.492

2.  Sleep and daytime sleepiness in retinitis pigmentosa patients.

Authors:  D Ionescu; H S Driver; E Heon; J Flanagan; C M Shapiro
Journal:  J Sleep Res       Date:  2001-12       Impact factor: 3.981

3.  Vision test variability in retinitis pigmentosa and psychosocial factors.

Authors:  Ava K Bittner; Mohamed A Ibrahim; Jennifer A Haythornthwaite; Marie Diener-West; Gislin Dagnelie
Journal:  Optom Vis Sci       Date:  2011-12       Impact factor: 1.973

4.  Development and validation of brief measures of positive and negative affect: the PANAS scales.

Authors:  D Watson; L A Clark; A Tellegen
Journal:  J Pers Soc Psychol       Date:  1988-06

5.  Quantification of sleepiness: a new approach.

Authors:  E Hoddes; V Zarcone; H Smythe; R Phillips; W C Dement
Journal:  Psychophysiology       Date:  1973-07       Impact factor: 4.016

6.  A global measure of perceived stress.

Authors:  S Cohen; T Kamarck; R Mermelstein
Journal:  J Health Soc Behav       Date:  1983-12

7.  Variability of visual field measurements in normal subjects and patients with retinitis pigmentosa.

Authors:  D F Ross; G A Fishman; L D Gilbert; R J Anderson
Journal:  Arch Ophthalmol       Date:  1984-07

8.  The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus.

Authors:  L B Krupp; N G LaRocca; J Muir-Nash; A D Steinberg
Journal:  Arch Neurol       Date:  1989-10

9.  A new method for measuring daytime sleepiness: the Epworth sleepiness scale.

Authors:  M W Johns
Journal:  Sleep       Date:  1991-12       Impact factor: 5.849

10.  Clinical findings and common symptoms in retinitis pigmentosa.

Authors:  J R Heckenlively; S L Yoser; L H Friedman; J J Oversier
Journal:  Am J Ophthalmol       Date:  1988-05-15       Impact factor: 5.258

View more
  7 in total

1.  Applying theories and interventions from behavioral medicine to understand and reduce visual field variability in patients with vision loss.

Authors:  Collin Rozanski; Jennifer A Haythornthwaite; Gislin Dagnelie; Ava K Bittner
Journal:  Med Hypotheses       Date:  2014-05-09       Impact factor: 1.538

2.  Visual field changes following implantation of the Argus II retinal prosthesis.

Authors:  Stanislao Rizzo; Claudia Belting; Laura Cinelli; Luca Allegrini
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-11-30       Impact factor: 3.117

3.  Patient-reported outcome measures in inherited retinal degeneration gene therapy trials.

Authors:  Gabrielle D Lacy; Maria Fernanda Abalem; David C Musch; Kanishka T Jayasundera
Journal:  Ophthalmic Genet       Date:  2020-02-26       Impact factor: 1.803

4.  Content generation for patient-reported outcome measures for retinal degeneration therapeutic trials.

Authors:  Gabrielle D Lacy; Maria Fernanda Abalem; Lilia T Popova; Erin P Santos; Gina Yu; Hanan Y Rakine; Julie M Rosenthal; Joshua R Ehrlich; David C Musch; K Thiran Jayasundera
Journal:  Ophthalmic Genet       Date:  2020-06-22       Impact factor: 1.803

5.  The Michigan Vision-Related Anxiety Questionnaire: A Psychosocial Outcomes Measure for Inherited Retinal Degenerations.

Authors:  Gabrielle D Lacy; Maria Fernanda Abalem; Chris A Andrews; Rebhi Abuzaitoun; Lilia T Popova; Erin P Santos; Gina Yu; Hanan Y Rakine; Natasha Baig; Joshua R Ehrlich; Abigail T Fahim; Kari H Branham; Bonnielin K Swenor; Paul R Lichter; Gislin Dagnelie; Joan A Stelmack; David C Musch; K Thiran Jayasundera
Journal:  Am J Ophthalmol       Date:  2020-12-09       Impact factor: 5.258

6.  First-in-human trial of a novel suprachoroidal retinal prosthesis.

Authors:  Lauren N Ayton; Peter J Blamey; Robyn H Guymer; Chi D Luu; David A X Nayagam; Nicholas C Sinclair; Mohit N Shivdasani; Jonathan Yeoh; Mark F McCombe; Robert J Briggs; Nicholas L Opie; Joel Villalobos; Peter N Dimitrov; Mary Varsamidis; Matthew A Petoe; Chris D McCarthy; Janine G Walker; Nick Barnes; Anthony N Burkitt; Chris E Williams; Robert K Shepherd; Penelope J Allen
Journal:  PLoS One       Date:  2014-12-18       Impact factor: 3.240

7.  Coping strategies, vision-related quality of life, and emotional health in managing retinitis pigmentosa: a survey study.

Authors:  Krithika Anil; Gulcan Garip
Journal:  BMC Ophthalmol       Date:  2018-01-30       Impact factor: 2.209

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.